Dabrafenib mechanism of action

Dabrafenib (Dabrafenib) is an oral drug used as an anti-tumor drug. Dabrafenib and trametinib are used together to treat a type of lung cancer called non-small cell lung cancer that has spread to other parts of the body (metastatic non-small cell lung cancer) and has a certain type of abnormal BRAF V600E gene.

Dabrafenibis an inhibitor of some mutant forms of BRAFkinase, targeting BRAF V600E, BRAF V600K and BRAF The in vitro IC50 values of V600Denzyme are 0.65, 0.5 and 1.84 nM respectively. Dabrafenibalso inhibits wild-type BRAF and CRAF kinase, its IC50 values are 3.2 and 5.0 respectively nM, as well as other kinases such as SIK1, NEK11 and LIMK1 at high concentrations. Some mutations in the BRAF gene, including those leading to BRAF V600E, can lead to constitutively activated BRAF kinase, thereby stimulating tumor cell growth. Dabrafenibinhibits cell growth in various BRAF V600 mutation-positive tumors in vitro and in vivo.

Dabrafenib and trimatinib target two different kinases in the RAS/RAF/MEK/ERK pathway. The combination of dabrafenib and trimetinib resulted in greater growth inhibition of BRAF V600 mutation-positive tumor cell lines in vitro and prolonged inhibition of tumor growth in BRAF V600 mutation-positive tumor xenografts compared with either agent alone. In the context of BRAFmutated colorectal cancer, induction of EGFR-mediated reactivation of the MAPK pathway is thought to be a mechanism of intrinsic resistance to BRAF inhibitors. If you want to get more high-quality information, you can contact Yaode , Yaode will do its best to learn more about high-quality overseas drugs for you.